Allogene Therapeutics Inc

Servier Amendment

On May 10, 2024, we entered into the Servier Amendment with Servier, pursuant to which the parties settled their disputes relating to each party’s performance under the Servier Agreement. The parties agreed to waive any and all outstanding claims that were asserted relating to alleged violations of the Servier Agreement, including all claims that such party was entitled to various payments or refunds from the other party under the Servier Agreement, and any and all claims that either party now has or may have in the future related to such outstanding claims, and mutual releases with respect to such claims were granted.

Additionally, the Servier Amendment expanded our territory under the Servier Agreement to include the European Union and the United Kingdom, and provides for an option to further expand our territory to include China and Japan. Under the Servier Amendment all of our future milestone payments (regulatory and sales) under the Servier Agreement are modified to be the same as, and to coincide with, Servier’s milestone payments to Cellectis under the Servier-Cellectis Agreement. The Servier Amendment also modified the royalties payable under the Servier Agreement. See Note 13. Subsequent Events to our condensed consolidated financial statements included elsewhere in this report for further description of the Servier Amendment.